Rivastigmine - Nottinghamshire APC
... action may be particularly important to patients with “sick sinus syndrome” or other supraventricular cardiac conduction conditions, such as sinoatrial or atrioventricular block. Gastrointestinal conditions: rivastigmine may cause increased gastric acid secretions. Patients with a history of ulcer d ...
... action may be particularly important to patients with “sick sinus syndrome” or other supraventricular cardiac conduction conditions, such as sinoatrial or atrioventricular block. Gastrointestinal conditions: rivastigmine may cause increased gastric acid secretions. Patients with a history of ulcer d ...
Rilpivirine: A second-generation nonnucleoside reverse
... ECHO and THRIVE studies concluded that rilpivirine, when combined with two NRTIs, was noninferior to efavirenz for reaching the endpoint of confirmed virological response (HIV-1 RNA level of <50 copies/mL) in adults with HIV infection not previously treated with antiretroviral therapy.17 The rilpivi ...
... ECHO and THRIVE studies concluded that rilpivirine, when combined with two NRTIs, was noninferior to efavirenz for reaching the endpoint of confirmed virological response (HIV-1 RNA level of <50 copies/mL) in adults with HIV infection not previously treated with antiretroviral therapy.17 The rilpivi ...
1. PACKAGE INSERT OXYIR® CII (oxycodone hydrochloride
... Low concentrations of oxycodone have been detected in breast milk. Withdrawal symptoms can occur in breast-feeding infants when maternal administration of an opioid analgesic is stopped. Ordinarily, nursing should not be undertaken while a patient is receiving OxyIR Capsules since oxycodone may be e ...
... Low concentrations of oxycodone have been detected in breast milk. Withdrawal symptoms can occur in breast-feeding infants when maternal administration of an opioid analgesic is stopped. Ordinarily, nursing should not be undertaken while a patient is receiving OxyIR Capsules since oxycodone may be e ...
Clinical Pharmacology
... chronotropic response due to baroreceptor reflex activation secondary to isoproterenolinduced vasodilatation. This effect shows that evaluation of drug responses must consider counterregulatory mechanisms. With age, central nervous system sedation by benzodiazepines is increased. This increase is cl ...
... chronotropic response due to baroreceptor reflex activation secondary to isoproterenolinduced vasodilatation. This effect shows that evaluation of drug responses must consider counterregulatory mechanisms. With age, central nervous system sedation by benzodiazepines is increased. This increase is cl ...
OTAREX®
... birth : hypotonia, movement disorders including extrapyramidal disorders, clonic movements, CNS depression, neonatal hypoxic conditions, or urinary retention. Therefore, this product should not be used during pregnancy Use in Breastfeeding (see Contraindications) It is not known whether this drug is ...
... birth : hypotonia, movement disorders including extrapyramidal disorders, clonic movements, CNS depression, neonatal hypoxic conditions, or urinary retention. Therefore, this product should not be used during pregnancy Use in Breastfeeding (see Contraindications) It is not known whether this drug is ...
AL Chemistry Group Project (TAS)
... Gefitinib is absorbed slowly after oral administration with mean bioavailability of 60%.Elimination is by metabolism (primarily CYP3A4) and excretion in feces. The elimination half-life is about 48 hours. Daily oral administration of gefitinib to cancer patients resulted in a 2-fold accumulation com ...
... Gefitinib is absorbed slowly after oral administration with mean bioavailability of 60%.Elimination is by metabolism (primarily CYP3A4) and excretion in feces. The elimination half-life is about 48 hours. Daily oral administration of gefitinib to cancer patients resulted in a 2-fold accumulation com ...
tobradex - Medsafe
... Corticosteroids have been found to be teratogenic in animal studies. Ocular administration of 0.1% dexamethasone resulted in 15.6% and 32.3% incidence of fetal anomalies in two groups of pregnant rabbits. Fetal growth retardation and increased mortality rates have been observed in rats with chronic ...
... Corticosteroids have been found to be teratogenic in animal studies. Ocular administration of 0.1% dexamethasone resulted in 15.6% and 32.3% incidence of fetal anomalies in two groups of pregnant rabbits. Fetal growth retardation and increased mortality rates have been observed in rats with chronic ...
SW_QA167_6Dosing_in_renal_impairmentFINAL
... may increase serum concentrations of the parent drug and consequent toxicity if the drug is metabolised to inactive metabolites (2). Many drugs and/or their phase I metabolites are eliminated by glucuronidation and the glucuronides are excreted by renal mechanisms. Therefore in patients with RI, glu ...
... may increase serum concentrations of the parent drug and consequent toxicity if the drug is metabolised to inactive metabolites (2). Many drugs and/or their phase I metabolites are eliminated by glucuronidation and the glucuronides are excreted by renal mechanisms. Therefore in patients with RI, glu ...
Ivermectin for the treatment of demodicosis
... 2. I understand that ivermectin is being dispensed for extralabel use, which in this case is being used at a higher dose rate, at a shorter dosing interval, in a different species, and for a different disease than the FDA-approved use. 3. I agree to follow instructions in using ivermectin as clear ...
... 2. I understand that ivermectin is being dispensed for extralabel use, which in this case is being used at a higher dose rate, at a shorter dosing interval, in a different species, and for a different disease than the FDA-approved use. 3. I agree to follow instructions in using ivermectin as clear ...
Focalin XR
... Focalin XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. The effectiveness of Focalin XR in the treatment of ADHD in patients aged 6 years and older was established in 2 placebo-controlled studies in patients meeting DSM-IV crit ...
... Focalin XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. The effectiveness of Focalin XR in the treatment of ADHD in patients aged 6 years and older was established in 2 placebo-controlled studies in patients meeting DSM-IV crit ...
Seizure threshold psychotropics (powerpoint file)
... serious risk patient/others (especially during the initial weeks of treatment). ...
... serious risk patient/others (especially during the initial weeks of treatment). ...
Risk of HIT
... Standard starting dose is 2 microg/kg per minute by continuous intravenous infusion Aadjusted to maintain the aPTT at 1.5–3 times baseline and not to exceed 100 seconds Metabolized by the liver Reduced dose and adjustment in; impaired liver function, critically ill patients, or cardiac surgery ...
... Standard starting dose is 2 microg/kg per minute by continuous intravenous infusion Aadjusted to maintain the aPTT at 1.5–3 times baseline and not to exceed 100 seconds Metabolized by the liver Reduced dose and adjustment in; impaired liver function, critically ill patients, or cardiac surgery ...
Page 1 of 3 CONSUMER INFORMATION PrPRED FORTE
... adequate and well controlled studies in pregnant women, therefore this product should be used with caution during pregnancy only if the potential benefit outweighs the potential risk to the fetus. Administration of corticosteroids to pregnant animals has been associated with abnormalities of fetal d ...
... adequate and well controlled studies in pregnant women, therefore this product should be used with caution during pregnancy only if the potential benefit outweighs the potential risk to the fetus. Administration of corticosteroids to pregnant animals has been associated with abnormalities of fetal d ...
NEW ZEALAND DATA SHEET CLOZARIL® (clozapine) 25mgand
... performed as follows: weekly during the first 18 weeks of therapy, and at least every 4 weeks thereafter throughout treatment. Monitoring must continue throughout treatment and for 4 weeks after complete discontinuation of Clozaril. Prescribing physicians should comply fully with the required safety ...
... performed as follows: weekly during the first 18 weeks of therapy, and at least every 4 weeks thereafter throughout treatment. Monitoring must continue throughout treatment and for 4 weeks after complete discontinuation of Clozaril. Prescribing physicians should comply fully with the required safety ...
(neomycin and polymyxin B sulfates and dexamethasone
... infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. The use of a combination drug with an anti-infective component ...
... infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. The use of a combination drug with an anti-infective component ...
Retisert - Bausch + Lomb
... acetonide caused abortions and malformations in a few surviving fetuses. There are no adequate and well-controlled studies in pregnant women. RETISERT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. 8.3 Nursing Mothers It is not known whether ...
... acetonide caused abortions and malformations in a few surviving fetuses. There are no adequate and well-controlled studies in pregnant women. RETISERT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. 8.3 Nursing Mothers It is not known whether ...
DOSE DEPENDENT EFFICACY OF LACOSAMIDE IN PROTECTION OF PENTYLENETETRAZOL Research Article
... Method: The study was conducted in albino rats of either sex, weighing between 100-150 gm. The animals were grouped into 6 groups, each compromised of 8 animals. Group I was treated with requisite volume of normal saline, group II received pentylenetetrazol (80mg/kg, i.p). Animals in group III, IV,V ...
... Method: The study was conducted in albino rats of either sex, weighing between 100-150 gm. The animals were grouped into 6 groups, each compromised of 8 animals. Group I was treated with requisite volume of normal saline, group II received pentylenetetrazol (80mg/kg, i.p). Animals in group III, IV,V ...
Protective Effect of Hypericum triquetrifolium Turra. on
... Acrolein interferes with the tissue antioxidant defense system, produces highly ROS, and interacts with protein amino acids causing structural and functional changes in enzymes 6,7. Experimental evidence suggests that oxidative stress is responsible for cyclophosphamide hepatotoxicity8,9. ...
... Acrolein interferes with the tissue antioxidant defense system, produces highly ROS, and interacts with protein amino acids causing structural and functional changes in enzymes 6,7. Experimental evidence suggests that oxidative stress is responsible for cyclophosphamide hepatotoxicity8,9. ...
Product information: Febuxostat (FBX)
... Febuxostat is a white crystalline powder with a pH of 5.0 in febuxostat solution (1 in 20,000 w/v). It is practically insoluble in water, slightly soluble in methanol, freely soluble in N, Ndimethylformamide and sparingly soluble in ethanol. The solubility of febuxostat is pH dependent in a wide-ran ...
... Febuxostat is a white crystalline powder with a pH of 5.0 in febuxostat solution (1 in 20,000 w/v). It is practically insoluble in water, slightly soluble in methanol, freely soluble in N, Ndimethylformamide and sparingly soluble in ethanol. The solubility of febuxostat is pH dependent in a wide-ran ...
Nucleoside/Nucleotide reverse transcriptase inhibitors
... Available as liquid formulation. Also approved for pediatric doses (1 month to 2 year-old children). ...
... Available as liquid formulation. Also approved for pediatric doses (1 month to 2 year-old children). ...
morphine (mor-feen) - DavisPlus
... Use Cautiously in: Head trauma;qintracranial pressure; Severe renal, hepatic, or pulmonary disease; Hypothyroidism; Seizure disorder; Adrenal insufficiency; History of substance abuse; Undiagnosed abdominal pain; Prostatic hyperplasia; Patients undergoing procedures that rapidly p pain (cordotomy, r ...
... Use Cautiously in: Head trauma;qintracranial pressure; Severe renal, hepatic, or pulmonary disease; Hypothyroidism; Seizure disorder; Adrenal insufficiency; History of substance abuse; Undiagnosed abdominal pain; Prostatic hyperplasia; Patients undergoing procedures that rapidly p pain (cordotomy, r ...
Phenanthrenes - Iowa Dental Association
... - Many dosage forms: 100mg caplet, 50 & 100mg chewable tablets, 100mg/5ml susp, gel caps - still the best first line agent due to good safety profile and reliable efficacy in acute pain - 800mg q 4 hours can be given initially, no analgesic value in doses above 3200mg/day ...
... - Many dosage forms: 100mg caplet, 50 & 100mg chewable tablets, 100mg/5ml susp, gel caps - still the best first line agent due to good safety profile and reliable efficacy in acute pain - 800mg q 4 hours can be given initially, no analgesic value in doses above 3200mg/day ...
Ranexa - Gilead
... efficacy were observed between older and younger patients. There were no differences in safety for patients 65 years compared to younger patients, but patients 75 years of age on RANEXA, compared to placebo, had a higher incidence of adverse events, serious adverse events, and drug discontinuation ...
... efficacy were observed between older and younger patients. There were no differences in safety for patients 65 years compared to younger patients, but patients 75 years of age on RANEXA, compared to placebo, had a higher incidence of adverse events, serious adverse events, and drug discontinuation ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.